This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $36.93, marking a +0.41% move from the previous day.
Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates
by Zacks Equity Research
Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK
by Zacks Equity Research
Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $38.32, moving +1.62% from the previous trading session.
Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $37.87, marking a -0.34% move from the previous day.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $36.55, marking a +1.67% move from the previous day.
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
by Zacks Equity Research
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
GSK's Jemperli Effective Against First-Line Endometrial Cancer
by Zacks Equity Research
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $35.04 in the latest trading session, marking a +1.92% move from the prior day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
by Zacks Equity Research
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $35.05, marking a +0.34% move from the previous day.
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?
by Zacks Equity Research
Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
by Zacks Equity Research
Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $33.72, moving +0.6% from the previous trading session.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $33.59 in the latest trading session, marking a -1.29% move from the prior day.
Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day.
Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?
by Zacks Equity Research
An FDA advisory committee recommended approving Pfizer's (PFE) and GSK's respective RSV vaccines for older adults. Currently, there are no RSV vaccines anywhere in the world.
Glaxo (GSK) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $34.58, marking a +0.93% move from the previous day.
The Zacks Analyst Blog Highlights Apple, Linde, Marsh & McLennan Companies, GSK and Expedia
by Zacks Equity Research
Apple, Linde, Marsh & McLennan Companies, GSK and Expedia are included in this Analyst Blog.
Top Analyst Reports for Apple, Linde & Marsh & McLennan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Linde plc (LIN) and Marsh & McLennan Companies, Inc. (MMC).